Anupam Rasayan India Limited, one of India’s leading custom synthesis and speciality chemicals companies, announced its financial results for the quarter and half year ended 30 September 2026. The company reported strong year-on-year growth in revenue and EBITDA, supported by business diversification, expansion into new end markets and continued progress across its strategic priorities. For the half year ended September 2026, Anupam Rasayan reported consolidated revenue of ₹1,489 crore, compared with ₹1,230 crore in H1 FY26, registering a growth of 21% year-on-year. The company’s EBITDA, including other income, increased by 38% to ₹377 crore from ₹273 crore in the corresponding period last year. Consequently, the company achieved an EBITDA margin of 25% during the first half of FY27.
Strategic Expansion and Business Diversification
Anand Desai, Managing Director, Anupam Rasayan India Limited, said, “H1 FY27 was marked by steady progress across our strategic priorities, expansion into new end markets and continued strengthening of our business portfolio. We are pleased to have achieved our highest-ever quarterly consolidated revenue during Q2 FY27, reflecting the resilience of our diversified business and the progress made across key segments.
Our focus continues to remain on building a globally integrated specialty chemicals platform by deepening relationships with existing customers, expanding into new applications and strengthening our capabilities across Pharmaceuticals, Performance Materials and other specialised segments.
During the quarter, we signed a six-year long-term supply agreement with a US-based speciality metal manufacturer. This marks an important step towards establishing our presence in the geological resources sector, diversifying our customer base and building a long-term strategic partnership with a global customer.
We also successfully completed the acquisition of a 50.07% stake in Bliss GVS Pharma, securing a controlling interest and marking a significant step in our vision of building a diversified pharmaceutical platform. The acquisition brings complementary capabilities in finished dosage formulations and provides opportunities to strengthen our presence across the pharmaceutical value chain, leverage operational and commercial synergies and expand our growth opportunities.
Going forward, we remain focused on disciplined execution, optimal utilization of our capital employed, successful integration of our strategic investments and continuous enhancement of our manufacturing and technological capabilities. We believe these initiatives will strengthen our business resilience, support sustainable growth and create long-term value for all stakeholders.”
Focus on Long-Term Sustainable Growth
Anupam Rasayan continues to strengthen its position in the global speciality chemicals market through customer partnerships, new market opportunities and strategic investments. The six-year supply agreement with a US-based speciality metal manufacturer and the acquisition of a controlling stake in Bliss GVS Pharma represent important milestones in its diversification strategy. As per the press release, the company will prioritise manufacturing efficiency, technological advancement, capital optimisation and successful integration of its investments to support long-term business growth and create sustainable value for stakeholders.
